PL1781782T3 - Zmodyfikowane polipeptydy zależne od witaminy K - Google Patents

Zmodyfikowane polipeptydy zależne od witaminy K

Info

Publication number
PL1781782T3
PL1781782T3 PL05786243T PL05786243T PL1781782T3 PL 1781782 T3 PL1781782 T3 PL 1781782T3 PL 05786243 T PL05786243 T PL 05786243T PL 05786243 T PL05786243 T PL 05786243T PL 1781782 T3 PL1781782 T3 PL 1781782T3
Authority
PL
Poland
Prior art keywords
derivatives
human factor
human
recombinant
polypeptides
Prior art date
Application number
PL05786243T
Other languages
English (en)
Inventor
Thomas Weimer
Stefan Schulte
Kay Hofmann
Hans-Peter Hauser
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL1781782T3 publication Critical patent/PL1781782T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05786243T 2004-08-17 2005-08-10 Zmodyfikowane polipeptydy zależne od witaminy K PL1781782T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04019485 2004-08-17
EP05786243A EP1781782B1 (en) 2004-08-17 2005-08-10 Modified vitamin k dependent polypeptides
PCT/EP2005/008678 WO2006018204A1 (en) 2004-08-17 2005-08-10 Modified vitamin k dependent polypeptides

Publications (1)

Publication Number Publication Date
PL1781782T3 true PL1781782T3 (pl) 2010-10-29

Family

ID=34926200

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05786243T PL1781782T3 (pl) 2004-08-17 2005-08-10 Zmodyfikowane polipeptydy zależne od witaminy K

Country Status (16)

Country Link
US (1) US8828939B2 (pl)
EP (1) EP1781782B1 (pl)
JP (1) JP2008509688A (pl)
KR (1) KR20070043051A (pl)
CN (1) CN101006175A (pl)
AT (1) ATE469216T1 (pl)
AU (1) AU2005274406B2 (pl)
BR (1) BRPI0514396A2 (pl)
CA (1) CA2592521A1 (pl)
DE (1) DE602005021509D1 (pl)
DK (1) DK1781782T3 (pl)
ES (1) ES2346072T3 (pl)
MX (1) MX2007001294A (pl)
PL (1) PL1781782T3 (pl)
RU (1) RU2396347C2 (pl)
WO (1) WO2006018204A1 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009528843A (ja) * 2006-03-06 2009-08-13 ヒューマジーン・インコーポレイテッド 組換えヒトトロンビンおよびフィブリノゲンの調製法
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US20100184672A1 (en) * 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
EP2209487A4 (en) * 2007-10-15 2012-06-20 Univ North Carolina VARIANTS OF HUMAN FACTOR IX WITH EXTENDED HALF-TIME
JP2011507919A (ja) * 2007-12-27 2011-03-10 バクスター・インターナショナル・インコーポレイテッド 修飾第ix因子
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP3581650B1 (en) 2008-09-15 2022-12-28 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
WO2010070137A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP2199387A1 (en) * 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102753575A (zh) * 2010-01-28 2012-10-24 诺沃—诺迪斯克保健股份有限公司 因子vii融合多肽
KR20180118808A (ko) 2010-07-09 2018-10-31 바이오버라티브 테라퓨틱스 인크. 인자 ix 폴리펩티드 및 이들의 사용 방법
JP6282467B2 (ja) 2010-10-05 2018-02-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー タンパク質を生産するための方法
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Mcbi 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
PT2922867T (pt) 2012-11-20 2021-10-29 Opko Biologics Ltd Método de aumentar o volume hidrodinâmico de polipéptidos anexando péptidos carboxi terminais de gonadotrofina
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
MY176901A (en) 2013-03-15 2020-08-26 Gladiator Biosciences Inc Gla domains as targeting agents
WO2015044836A1 (en) 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CA2989990C (en) 2015-06-19 2024-03-12 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
JP7319187B2 (ja) 2016-07-11 2023-08-01 オプコ バイオロジクス リミテッド 長時間作用型凝固因子viiおよびその製造方法
BR112020003945A2 (pt) 2017-09-05 2020-09-08 GLAdiator Biosciences, Inc. entrega de cargas úteis a células-tronco
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DK0506821T3 (da) * 1989-12-29 1998-03-30 Zymogenetics Inc Hybridt protein C
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
EP0917566B1 (de) * 1996-06-11 2004-09-22 Roche Diagnostics GmbH Rekombinante blutgerinnungsproteasen
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
NL1007767C2 (nl) 1997-12-11 1999-06-14 Dsm Nv Werkwijze voor de bereiding van een polyamide nanocomposiet samenstelling.
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第vii因子改変体
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7176288B2 (en) 2000-09-13 2007-02-13 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
ES2226533B1 (es) 2002-07-25 2005-12-16 Fundacio Privada I Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Nuevas variantes alelicas en el gen del factor vii.
EP1546202B1 (en) 2002-09-25 2007-08-22 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
JP4472526B2 (ja) 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第VII因子または第VIIa因子変種
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
WO2004108763A2 (en) 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
JP2007509843A (ja) 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第VII/VIIa因子活性を有するハイブリッド分子

Also Published As

Publication number Publication date
KR20070043051A (ko) 2007-04-24
DE602005021509D1 (de) 2010-07-08
EP1781782B1 (en) 2010-05-26
MX2007001294A (es) 2008-03-04
AU2005274406B2 (en) 2010-07-01
CN101006175A (zh) 2007-07-25
JP2008509688A (ja) 2008-04-03
RU2007105677A (ru) 2008-08-20
US20090130060A1 (en) 2009-05-21
ES2346072T3 (es) 2010-10-08
BRPI0514396A2 (pt) 2009-05-12
WO2006018204A1 (en) 2006-02-23
ATE469216T1 (de) 2010-06-15
EP1781782A1 (en) 2007-05-09
AU2005274406A1 (en) 2006-02-23
RU2396347C2 (ru) 2010-08-10
US8828939B2 (en) 2014-09-09
CA2592521A1 (en) 2006-02-23
DK1781782T3 (da) 2010-08-23

Similar Documents

Publication Publication Date Title
PL1781782T3 (pl) Zmodyfikowane polipeptydy zależne od witaminy K
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
MX362028B (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
NO20052276D0 (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
WO2005072129A9 (en) Production of host cells containing mutiple integrating vectors by serial transduction
IN2012DN02981A (pl)
MX2007010552A (es) Plantas de arroz resistentes a herbicidas, polinucleotidos que codifican proteinas de subunidad grande de acido acetohidroxi sintasa resistentes a herbicidas, y sus metodos de uso.
WO2005080581A3 (en) Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
WO2003088899A3 (en) Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
WO2004053137A3 (en) Method for protein production
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
PL2066790T3 (pl) Galaktozylotransferaza
WO2005007803A3 (en) Selection free growth of host cells containing multiple integrating vectors
WO2004078112A3 (en) Apoptosis inducing gene
WO2002079224A3 (en) Isolated human nadph oxidase, nucleic acid molecules encoding said proteins, and uses thereof
WO2002034882A3 (en) Genes regulating programmed cell death
CR20230429A (es) Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación IX, y su uso
MXPA05008925A (es) Ciclooxigenasa-3 humana y usos de la misma.
WO2002079430A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2003087375A8 (en) Cartilage differentiation regulating gene
WO2003074666A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2003074669A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
RU2006145771A (ru) СТИМУЛЯТОР СИНТЕЗА БЕЛКА nef(A)-hum В КЛЕТКАХ ЭУКАРИОТ
WO2002070663A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof